Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large-scale studies.
Verghese G, Li M, Liu F, Lohan A, Kurian NC, Meena S, Gazinska P, Shah A, Oozeer A, Chan T, Opdam M, Linn S, Gillett C, Alberts E, Hardiman T, Jones S, Thavaraj S, Jones JL, Salgado R, Pinder SE, Rane S, Sethi A, Grigoriadis A. Verghese G, et al. Among authors: opdam m. J Pathol. 2023 Aug;260(4):376-389. doi: 10.1002/path.6088. Epub 2023 May 25. J Pathol. 2023. PMID: 37230111 Free PMC article.
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.
Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Hauptmann M, van Schaik RH, Berns EM, Vermorken JB, van Diest PJ, Linn SC. Beelen K, et al. Among authors: opdam m. Breast Cancer Res Treat. 2013 Jun;139(3):649-55. doi: 10.1007/s10549-013-2568-0. Epub 2013 Jun 5. Breast Cancer Res Treat. 2013. PMID: 23736997 Free PMC article. Clinical Trial.
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
Szijgyarto Z, Flach KD, Opdam M, Palmieri C, Linn SC, Wesseling J, Ali S, Bliss JM, Cheang MCU, Zwart W, Coombes RC. Szijgyarto Z, et al. Among authors: opdam m. Breast Cancer Res Treat. 2019 May;175(1):149-163. doi: 10.1007/s10549-018-05110-x. Epub 2019 Jan 24. Breast Cancer Res Treat. 2019. PMID: 30680659 Free PMC article.
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
de Boo LW, Jóźwiak K, Joensuu H, Lindman H, Lauttia S, Opdam M, van Steenis C, Brugman W, Kluin RJC, Schouten PC, Kok M, Nederlof PM, Hauptmann M, Linn SC. de Boo LW, et al. Among authors: opdam m. Br J Cancer. 2022 Jun;126(10):1401-1409. doi: 10.1038/s41416-022-01711-y. Epub 2022 Feb 5. Br J Cancer. 2022. PMID: 35124703 Free PMC article. Clinical Trial.
50 results